[
  {
    "ts": null,
    "headline": "2 Reasons to Like ZTS (and 1 Not So Much)",
    "summary": "Over the last six months, Zoetis’s shares have sunk to $129.91, producing a disappointing 16.4% loss - a stark contrast to the S&P 500’s 7.2% gain. This may have investors wondering how to approach the situation.",
    "url": "https://finnhub.io/api/news?id=1c07ce84ddc26feb9f4deedaea1afed7f4c367cfa8b955522147ee7fe47ca647",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1772215292,
      "headline": "2 Reasons to Like ZTS (and 1 Not So Much)",
      "id": 139255721,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Over the last six months, Zoetis’s shares have sunk to $129.91, producing a disappointing 16.4% loss - a stark contrast to the S&P 500’s 7.2% gain. This may have investors wondering how to approach the situation.",
      "url": "https://finnhub.io/api/news?id=1c07ce84ddc26feb9f4deedaea1afed7f4c367cfa8b955522147ee7fe47ca647"
    }
  },
  {
    "ts": null,
    "headline": "Merck Says Keytruda Plus Padcev Decreases Risk of Death in Bladder Cancer Trial",
    "summary": "Merck (MRK) said Friday that a phase 3 trial showed Keytruda plus Padcev decreased the risk of event",
    "url": "https://finnhub.io/api/news?id=1f0637781ddaad77a0fc122306753166eea5982f984e3028eca5e30880402123",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1772210388,
      "headline": "Merck Says Keytruda Plus Padcev Decreases Risk of Death in Bladder Cancer Trial",
      "id": 139254395,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Merck (MRK) said Friday that a phase 3 trial showed Keytruda plus Padcev decreased the risk of event",
      "url": "https://finnhub.io/api/news?id=1f0637781ddaad77a0fc122306753166eea5982f984e3028eca5e30880402123"
    }
  },
  {
    "ts": null,
    "headline": "The Zacks Analyst Blog Highlights Meta Platforms, Netflix, Pfizer, SIFCO Industries and Altigen Communications",
    "summary": "Meta's AI push lifts engagement, Netflix eyes revenue doubling by 2030, and Pfizer leans on new launches to offset looming patent cliffs.",
    "url": "https://finnhub.io/api/news?id=28f5d24c78620498793f0ec8b1c780ca5a1a0428f2368560b7c84ff7715f05bc",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1772206200,
      "headline": "The Zacks Analyst Blog Highlights Meta Platforms, Netflix, Pfizer, SIFCO Industries and Altigen Communications",
      "id": 139254330,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Meta's AI push lifts engagement, Netflix eyes revenue doubling by 2030, and Pfizer leans on new launches to offset looming patent cliffs.",
      "url": "https://finnhub.io/api/news?id=28f5d24c78620498793f0ec8b1c780ca5a1a0428f2368560b7c84ff7715f05bc"
    }
  },
  {
    "ts": null,
    "headline": "Amneal Pharmaceuticals Q4 Earnings Call Highlights",
    "summary": "Amneal Pharmaceuticals (NASDAQ:AMRX) reported fourth-quarter and full-year 2025 results and outlined its 2026 outlook, highlighting growth across the business, expanding complex product launches, and continued investment in specialty brands, biosimilars, and GLP-1 manufacturing capacity. 2025 resul",
    "url": "https://finnhub.io/api/news?id=4b49a3bb162436b875511239f280d0abf4d15674be49320860bcbc4e7aa5d36d",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1772205867,
      "headline": "Amneal Pharmaceuticals Q4 Earnings Call Highlights",
      "id": 139250070,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Amneal Pharmaceuticals (NASDAQ:AMRX) reported fourth-quarter and full-year 2025 results and outlined its 2026 outlook, highlighting growth across the business, expanding complex product launches, and continued investment in specialty brands, biosimilars, and GLP-1 manufacturing capacity. 2025 resul",
      "url": "https://finnhub.io/api/news?id=4b49a3bb162436b875511239f280d0abf4d15674be49320860bcbc4e7aa5d36d"
    }
  },
  {
    "ts": null,
    "headline": "PADCEV™ + Keytruda® Cuts Risk of Recurrence or Death by Nearly 50% in Cisplatin-Eligible Muscle-Invasive Bladder Cancer",
    "summary": "NEW YORK & TOKYO, February 27, 2026--Pfizer Inc. (NYSE: PFE) and Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, \"Astellas\") today announced positive results from the Phase 3 EV-304 clinical trial (also known as KEYNOTE-B15) for PADCEVTM (enfortumab vedotin), a Nectin-4 directed antibody-drug conjugate, in combination with Keytruda® (pembrolizumab), a PD-1 inhibitor, in patients with muscle-invasive bladder cancer (MIBC) eligible for cisplatin-based chemotherapy. Perioperative",
    "url": "https://finnhub.io/api/news?id=ab1ee9306a681f8dda76b22ca6b79534e132466c06efc30bb32d6792dc0f13eb",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1772204400,
      "headline": "PADCEV™ + Keytruda® Cuts Risk of Recurrence or Death by Nearly 50% in Cisplatin-Eligible Muscle-Invasive Bladder Cancer",
      "id": 139250071,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "NEW YORK & TOKYO, February 27, 2026--Pfizer Inc. (NYSE: PFE) and Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, \"Astellas\") today announced positive results from the Phase 3 EV-304 clinical trial (also known as KEYNOTE-B15) for PADCEVTM (enfortumab vedotin), a Nectin-4 directed antibody-drug conjugate, in combination with Keytruda® (pembrolizumab), a PD-1 inhibitor, in patients with muscle-invasive bladder cancer (MIBC) eligible for cisplatin-based chemotherapy. Perioperative",
      "url": "https://finnhub.io/api/news?id=ab1ee9306a681f8dda76b22ca6b79534e132466c06efc30bb32d6792dc0f13eb"
    }
  },
  {
    "ts": null,
    "headline": "Pfizer’s New BRAFTOVI Approval Broadens Oncology Reach And Investor Debate",
    "summary": "Pfizer (NYSE:PFE) received full FDA approval for BRAFTOVI (encorafenib) with cetuximab and fluorouracil-based chemotherapy as a first-line treatment for adults with BRAF V600E-mutant metastatic colorectal cancer. The approval converts BRAFTOVI’s prior accelerated status to full approval and is supported by data from the global Phase 3 BREAKWATER trial. The decision recognizes benefits in both progression-free survival and overall survival for this aggressive colorectal cancer subtype. For...",
    "url": "https://finnhub.io/api/news?id=86801a9dbc781fc65731dc2d1aa6229d61905025ec06c6265dff11e4d558e79d",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1772201527,
      "headline": "Pfizer’s New BRAFTOVI Approval Broadens Oncology Reach And Investor Debate",
      "id": 139250072,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Pfizer (NYSE:PFE) received full FDA approval for BRAFTOVI (encorafenib) with cetuximab and fluorouracil-based chemotherapy as a first-line treatment for adults with BRAF V600E-mutant metastatic colorectal cancer. The approval converts BRAFTOVI’s prior accelerated status to full approval and is supported by data from the global Phase 3 BREAKWATER trial. The decision recognizes benefits in both progression-free survival and overall survival for this aggressive colorectal cancer subtype. For...",
      "url": "https://finnhub.io/api/news?id=86801a9dbc781fc65731dc2d1aa6229d61905025ec06c6265dff11e4d558e79d"
    }
  },
  {
    "ts": null,
    "headline": "Novavax Stock Gains as Q4 Earnings & Sales Beat Estimates",
    "summary": "NVAX stock jumps 17% after Q4 swings to a surprise profit on strong licensing revenues and lower costs, with sales soaring 67% year over year.",
    "url": "https://finnhub.io/api/news?id=c0a3e5729f62635074b4baa861c168f48fd44b21fbb9e7e02522842088e155fa",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1772198760,
      "headline": "Novavax Stock Gains as Q4 Earnings & Sales Beat Estimates",
      "id": 139250073,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "NVAX stock jumps 17% after Q4 swings to a surprise profit on strong licensing revenues and lower costs, with sales soaring 67% year over year.",
      "url": "https://finnhub.io/api/news?id=c0a3e5729f62635074b4baa861c168f48fd44b21fbb9e7e02522842088e155fa"
    }
  },
  {
    "ts": null,
    "headline": "Pfizer (PFE) Secures Full FDA Approval for BRAFTOVI as First-Line Treatment in mCRC",
    "summary": "Pfizer Inc. (NYSE:PFE) is one of the most undervalued stocks under $30 to buy. On February 24, the US FDA granted full approval to Pfizer’s BRAFTOVI (encorafenib) in combination with cetuximab and fluorouracil-based chemotherapy for the first-line treatment of adults with BRAF V600E-mutant metastatic colorectal cancer/mCRC. This decision converts a previous accelerated approval into a […]",
    "url": "https://finnhub.io/api/news?id=e99030dee0e62b38a95c42f2dfdc3ab926b1fe43e6c53f00b12ec72d7786c644",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1772193704,
      "headline": "Pfizer (PFE) Secures Full FDA Approval for BRAFTOVI as First-Line Treatment in mCRC",
      "id": 139247345,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Pfizer Inc. (NYSE:PFE) is one of the most undervalued stocks under $30 to buy. On February 24, the US FDA granted full approval to Pfizer’s BRAFTOVI (encorafenib) in combination with cetuximab and fluorouracil-based chemotherapy for the first-line treatment of adults with BRAF V600E-mutant metastatic colorectal cancer/mCRC. This decision converts a previous accelerated approval into a […]",
      "url": "https://finnhub.io/api/news?id=e99030dee0e62b38a95c42f2dfdc3ab926b1fe43e6c53f00b12ec72d7786c644"
    }
  },
  {
    "ts": null,
    "headline": "Beam Therapeutics: Great Potential, But Patience Is Needed",
    "summary": "Beam Therapeutics: Great Potential, But Patience Is Needed",
    "url": "https://finnhub.io/api/news?id=3dd2460c690fd19925ab11b731e5b6cb375683df4285acee733c8163a3b05552",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1772185241,
      "headline": "Beam Therapeutics: Great Potential, But Patience Is Needed",
      "id": 139249340,
      "image": "",
      "related": "PFE",
      "source": "SeekingAlpha",
      "summary": "",
      "url": "https://finnhub.io/api/news?id=3dd2460c690fd19925ab11b731e5b6cb375683df4285acee733c8163a3b05552"
    }
  },
  {
    "ts": null,
    "headline": "Novavax Q4 Earnings Call Highlights",
    "summary": "Novavax (NASDAQ:NVAX) executives told investors the company made “significant progress” in 2025 executing a strategy centered on partnering its Matrix-M adjuvant technology and advancing a smaller, earlier-stage internal pipeline, while continuing to reduce operating expenses and stabilize the balan",
    "url": "https://finnhub.io/api/news?id=a0cf7d1cd93678bd8e636fdfc1de6336add63fc7d938d592d9af42c1738f4a28",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1772168846,
      "headline": "Novavax Q4 Earnings Call Highlights",
      "id": 139243842,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Novavax (NASDAQ:NVAX) executives told investors the company made “significant progress” in 2025 executing a strategy centered on partnering its Matrix-M adjuvant technology and advancing a smaller, earlier-stage internal pipeline, while continuing to reduce operating expenses and stabilize the balan",
      "url": "https://finnhub.io/api/news?id=a0cf7d1cd93678bd8e636fdfc1de6336add63fc7d938d592d9af42c1738f4a28"
    }
  },
  {
    "ts": null,
    "headline": "Ionis Pharmaceuticals: Digesting Recent Events",
    "summary": "Ionis Pharmaceuticals: Digesting Recent Events",
    "url": "https://finnhub.io/api/news?id=b48be207fbdc717ae55d144e3d4bbfa032cd44e3cc77403d05860d0db3a3e855",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1772160856,
      "headline": "Ionis Pharmaceuticals: Digesting Recent Events",
      "id": 139244654,
      "image": "",
      "related": "PFE",
      "source": "SeekingAlpha",
      "summary": "",
      "url": "https://finnhub.io/api/news?id=b48be207fbdc717ae55d144e3d4bbfa032cd44e3cc77403d05860d0db3a3e855"
    }
  },
  {
    "ts": null,
    "headline": "Love Dividends? 1 Stock to Buy Now With a Yield Over 6%.",
    "summary": "Even amid volatility, Pfizer keeps rewarding shareholders year after year.",
    "url": "https://finnhub.io/api/news?id=08710dabd81aeb9738c97a48c002d085ebdef83200fd51d6ca73877dbc7076b9",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1772152202,
      "headline": "Love Dividends? 1 Stock to Buy Now With a Yield Over 6%.",
      "id": 139242887,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Even amid volatility, Pfizer keeps rewarding shareholders year after year.",
      "url": "https://finnhub.io/api/news?id=08710dabd81aeb9738c97a48c002d085ebdef83200fd51d6ca73877dbc7076b9"
    }
  }
]